Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

32.39 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

May 03, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

What 7 Analyst Ratings Have To Say About Stoke Therapeutics ↗

April 26, 2023

Via Benzinga

Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know ↗

March 07, 2023

Via Benzinga

6 Analysts Have This to Say About Stoke Therapeutics ↗

March 07, 2023

Via Benzinga

Expert Ratings for Stoke Therapeutics ↗

January 11, 2023

Via Benzinga

Stoke Therapeutics Earnings Perspective: Return On Capital Employed ↗

December 26, 2022

Via Benzinga

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 25, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 15, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 06, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 27, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 09, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday ↗

December 05, 2022

Via Benzinga

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

December 02, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

December 02, 2022

On Friday, 72 companies hit new 52-week lows.

Via Benzinga

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 29, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

November 22, 2022

During Tuesday's trading, 160 companies set new 52-week lows.

Via Benzinga

BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗

November 17, 2022

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program ↗

November 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 14, 2022

Monday saw 33 companies set new 52-week lows.

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 14, 2022

Gainers

Via Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗

November 14, 2022

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 14, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 10, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study ↗

August 25, 2022

Stoke Therapeutics (NASDAQ: STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.